ChromaDex and JQMS Announce Exclusive Sales and Marketing Agreement for GMP Compliance Services
IRVINE, Calif., May 28, 2014 /PRNewswire/ — ChromaDex Corp.( ) (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, and Joy’s Quality Management Systems, Inc. (JQMS), a leading consulting firm for regulatory compliance and training services, announced today that ChromaDex has been designated as the exclusive sales and marketing agent for JQMS’ services.
These services include consulting, auditing, inspection, validation, and training services for GMP compliance in the dietary supplement, food and pharmaceutical markets. JQMS, founded by Joy A. Joseph, is recognized as one of the leaders in its field. This collaboration, which is effective as of June 1, 2014, will significantly expand the suite of GMP-related services that ChromaDex can provide to existing and potential customers.
“JQMS and ChromaDex are both leaders in their respective fields,” said Frank L. Jaksch Jr., founder and CEO of ChromaDex. “This agreement enables us to further cement ourselves as a full service provider of GMP services for our clients. We can now offer a complete suite of GMP related services from auditing and inspection services to analytical testing to GRAS dossier preparation. With this partnership, ChromaDex can be considered a true one-stop shop for clients needing help with almost any issue or problem related to GMP compliance.”
“We feel this is a great move for both companies. We are extremely excited to move forward, as together, we are able to provide all of our clients with a total package of services. In today’s environment, regulatory compliance has become an even greater challenge. This partnership provides our combined customer base with the expertise and services needed to meet and overcome present and future regulatory challenges. This partnership enables JQMS to serve our current client base from a more strategic perspective and allows us to expand our offerings globally,” said Joy A. Joseph, CEO of JQMS.
ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as “phytochemicals”), chemistry and analytical testing services and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure(®) pterostilbene; ProC3G(®), a natural black rice containing cyanidin-3-glucoside; PURENERGY(®), a caffeine-pTeroPure(®) cocrystal; and NIAGEN(TM), its recently launched branded nicotinamide riboside, a novel next-generation no-flush B vitamin. To learn more about ChromaDex, visit www.chromadex.com.
Joy’s Quality Management Systems, Inc., was founded in 2004 to develop science based products and assist the Dietary Supplement Industry with implementing the Dietary Supplement “Good Manufacturing Practice Regulations”. Since that time, the company has grown to offer a complete range of regulatory compliance services for the dietary supplement, food, and pharmaceutical industries. Our experts have more than 75 years of combined experience in manufacturing, auditing, OSHA safety, formulations, process development, validation, regulatory affairs, training, and facility construction management. The firm’s mission is to work with companies to establish appropriate practices and procedures in order to provide consumers with safe, high quality products.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Media Inquiries:
ChromaDex Company Contact:
Laura Kelly, Executive Assistant
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease. -------------------------------------
SOURCE ChromaDex Corp.